Peter Reynolds

The life and times of Peter Reynolds

CLEAR and GroGlo Establish First UK Clinical Trials on Cannabis for Chronic Pain.

with 15 comments

groglo banner

CLEAR has formed a partnership with the research arm of GroGlo, a UK-based manufacturer of high power, LED, horticultural grow lighting.

The plan is to grow cannabis under a Home Office licence for the production of cannabis oil, both as a dietary supplement and for the development of medical products.  To begin with, a low-THC crop of industrial hemp will be planted.  We will be using the finola strain, originally developed in Finland and known for its short stature and early flowering. Unlike hemp grown for fibre, finola is usually grown for seed and only reaches a height of 160 – 180 cm but we will be removing male plants before they produce pollen and cultivating the female plants to produce the maximum yield of oil from their flowering tops.

Finola Industrial Hemp

Finola Industrial Hemp

The low-THC oil will be marketed as a dietary supplement, commonly known as CBD oil. There is already a burgeoning market in the UK for CBD products, all of which is currently imported from Europe or the USA.  In the USA, the CBD products market was said to be worth $85 million in 2015 so there is huge potential here at home. Aside from the benefit of being UK grown and processed, we anticipate achieving a CBD concentration of about 40%, which is higher than most products already on the market.

Cultivation will be in glasshouses supplemented with LED lighting.  GroGlo already has an established glasshouse facility in the east of England.  Initial trials will experiment with adjusting the LED technology to provide a changing blend of light wavelengths at different stages of plant growth.  This is GroGlo’s area of expertise -combining LED lighting and plant sciences, including existing relationships with some of Europe’s top universities. Professor Mick Fuller, GroGlo’s director of plant science, will lead this research and development process.

Professor Mick Fuller

Professor Mick Fuller

During the R&D phase, CO2 extraction of oil will be carried out under laboratory conditions at universities in York and Nottingham which already have extensive experience of the process. Each crop will be measured for yield, cannabinoid and terpene content using high pressure liquid chromatography (HPLC).  Safety testing will also look for the presence of heavy metals and other contaminants.  The results of testing will be fed back into cultivation and extraction processes to maximise yield and quality.

It is anticipated that the first batches of low-THC oil will be ready for market in six months.  We are already in discussions with potential distributors and wholesalers. The CBD market in the UK is ripe for an effective marketing campaign which could build a very substantial business for whoever gets it right.

Once we are successfully achieving our production goals with low-THC cannabis, the same testing and development process will begin with high-THC varieties of cannabis.  The aim will be to produce a range of oils extracted from single strains, selectively bred and stabilised for different THC:CBD ratios.

Professor Fuller says that GroGlo lighting products “are in use worldwide to grow a range of crops, but some 60% of sales currently come from overseas users growing cannabis for legitimate medical use.”  He explains that there is an emerging market for all sorts of nutritional and medicinal plant products but cannabis shows particular promise. GW Pharmaceuticals is the only UK company to enter this market and it has become a world leader, despite the current restrictive legislation.  He says:  “Together with CLEAR we believe we can help bring a range of safe, high quality UK-produced cannabis products to market within a matter of two to three years.”

A key issue in the development of a successful medicinal cannabis product is the method of delivery.  Smoking is not an acceptable solution as inhaling the products of combustion is an unhealthy practice but one of the great benefits of cannabis smoked as medicine is very accurate self-titration.  That is the effects of inhaled cannabis are felt almost instantly and so the patient knows when they have taken enough or when they need more to achieve the required analgesic effect.

The oral mucosal spray developed for Sativex is unpopular with patients, many complain of mouth sores from its use and it was developed at least as much with the objective of deterring ‘recreational’ use of the product as with delivering the medicine effectively. It strangles the therapeutic benefits of the cannabis oil of which Sativex is composed in order to comply with the concerns of the medicines regulators about ‘diversion’ of the product into what they would term ‘misuse’.  Absorption of the oil is quicker through the mucous membranes of the inside of the mouth than through the gastrointestinal system but, inevitably, some of the oil is swallowed and the pharmacology of cannabis when processed through the gut and the liver is very different.

We believe the best option is a vapouriser device and our intention is to source a ‘vape pen’ of sufficient quality to operate within clinical standards of consistency and safety. Vapourising cannabis oil avoids inhaling the products of combustion but still enables accurate self-titration of dose.  A vape pen would provide a handy, convenient and very effective method of consuming medicinal cannabis.  However, aside from the technology itself, initial research shows that vapour is more effectively produced when the oil is blended with either vegetable glycerin (VG) or propylene glycol (PG).  Establishing the correct ratio of VG or PG to the oil is another important task.

We anticipate that clinical trials for the use of cannabis oil in treating chronic pain could start within two years.  We want to compare different oils, ranging from high-CBD to equal ratios of THC:CBD and high-THC content. Prior to that we have to overcome the challenges of cultivation, oil extraction, vapouriser development and assemble the necessary research team and gain ethical approval for the trials.  Recruitment for the trials will start in about 18 months time.  If you wish to be considered please email ‘’ with brief details of your condition (no more than 100 words). Do not expect to hear anything for at least 12 months but your details will be passed to the research team as a potential candidate.

Mike Harlington, Managing Director of GroGlo

Mike Harlington, Managing Director of GroGlo

CLEAR is promoting this venture simply because someone needs to do something to make this happen. For all the campaigning and lobbying of MPs and ministers, at the end of the day, the plants have to be grown and the various legislative hoops have to be jumped through. We cannot wait any longer for a radical change in the law. We have to progress through the government’s regulatory regime if we want to bring real therapeutic benfit to patients.

This opportunity arises because of the vision of GroGlo’s managing director, Mike Harlington and the team of experts he has built around him. There is huge demand for legitimate medicinal cannabis products in the UK which is only going to increase with the inevitable progress towards law reform and increasing awareness of the benefits of cannabis. Together, CLEAR and GroGlo are bringing the great hope that medicinal cannabis offers closer to reality than ever before.


15 Responses

Subscribe to comments with RSS.

  1. Hi Peter
    I have tried to register: and I get this message:
    Delivery to the following recipient failed permanently:

    Technical details of permanent failure:
    Google tried to deliver your message, but it was rejected by the server for the recipient domain by [].

    The error that the other server returned was:
    550 Unrouteable address

    Can I email you personally?

    Take care

    Jim G


    April 23, 2016 at 1:21 pm

    • Please try again. The mailbox has been checked and is working.

      Peter Reynolds

      April 23, 2016 at 1:41 pm

  2. Hello my name is Darren Parker, I was diagnosed with HIV last February and I am interested in the beneficial properties of cannabis as it helps with aches and pains and it helps me to eat, I look forward to hearing back from you, thank you
    Darren Parker

    Darren parker

    April 23, 2016 at 1:38 pm

    • Please email ‘’ to register your interest

      Peter Reynolds

      April 23, 2016 at 1:42 pm

  3. I’m really interested in seeing how this progresses as my wife suffers from Fibromyalgia and has a great deal of chronic pain.

    It says above that “The plan is to grow cannabis under a Home Office licence” – does that mean the licence has been granted?


    April 24, 2016 at 12:59 am

    • So in a nutshell you are saying….. this is another company trying to break into the Cbd oil market and your “dressing up” and adding a spin to the fact that you are endorsing an outfit that is copying an already existing kana-vape pen business.


      April 27, 2016 at 6:07 am

      • No Chantelle, you are incorrect. Firstly, I strongly warn against Kanavape. It offers no lab tests or verification of its oil. Even by its own claim of 5% CBD it is very weak. It is a company that has invested in marketing but very little in demonstrating its product contents and safety.

        Secondly, the venture between CLEAR and GroGlo will be the first UK grown and produced CBD oil and we are anticipating 40% CBD content.

        Thirdly, clinical trials will commence with both CBD and high THC oils

        Peter Reynolds

        April 27, 2016 at 9:20 am

  4. Reblogged this on nearlydead.


    April 25, 2016 at 8:43 am

  5. Reblogged this on lifeaccordingtobet.


    April 27, 2016 at 8:55 am

  6. I live in the eastern counties, how do apply for a job?

    Simon Riggall

    April 27, 2016 at 11:15 am

  7. Hello I would like to register my for patient trials of canabis use for on medical trials and ask for further information?
    I suffer from chronic pain arising from a rangle of difficult health problems I suffer Endometriosis/LoinPain Harmaturia Syndrome/Adhesions/IBS/Fibromyalgia/Depression. I am currently having zero quality of life.


    May 14, 2016 at 10:35 pm

  8. I already use CBD for relief of my Chronic illness, tho the hardest thing is to wade through the amount that are made with LOW GRADE HEMP. I have found that high grade strains CBD products work better. I have PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS & CBD is the best treatment option for me currently available. I was informed about possibly apply for Sativex, but apart from keeping a balance & preventing a build up of tolerance for Indicas (used in conjuction am/pm s/I), it is not that usfull to me as I need the higher CBD content for relief. The CBD oil I currently use is 20% CBD in coconut oil. Will your grade be as high? Cannabis is my only medicine.

    cris clarion

    May 25, 2016 at 4:53 am

  9. […] CLEAR and GroGlo Establish First UK Clinical Trials on Cannabis for Chronic Pain. – Aside from the benefit of being UK grown and processed, we anticipate achieving a CBD concentration of about 40%, which is higher than most products … including existing relationships with some of Europe’s top universities. Professor Mick Fuller … […]

  10. The most comprehensive and very effectively thought out write up I have discovered on this subject on the net. Keep on writing, I will maintain on coming by to read your new content. This really is my fourth time coming by your blog.

    heartburn relief

    December 9, 2016 at 5:04 pm

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: